Precigen, Inc. (PGEN) Misses Q2 EPS by 13c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Precigen, Inc. (PGEN) Reports Phase 1b Study of AG019 ActoBiotics Met Primary Endpoint Assessing Safety and Tolerability
August 10, 2020 7:36 AM EDTPrecigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (NASDAQ: PGEN), today announced it has met the primary endpoint assessing safety and tolerability in the Phase 1b monotherapy portion of the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics for the treatment of early-onset type 1 diabetes (T1D) (clinical trial identifier:... More
Precigen, Inc. (PGEN) Provides Six-month Follow-up Data from Phase I Study of INXN-4001
August 6, 2020 7:54 AM EDTPrecigen Triple-Gene, a clinical stage cardiovascular gene therapy company and majority-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced six-month follow-up data from the Phase I trial of INXN-4001 (clinical trial identifier: NCT03409627), a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure.... More
